All In Biotech

Drug Trial Radar · NCT01519791

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

880

Actual

Start

Jan 2012

Primary completion

Jul 2014

Study completion Sep 2015

Sponsor

Lead sponsor
UCB Pharma SAUCB
Sponsor type
Industry
First posted
Jan 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug (DMARD)-naïve adults with early active Rheumatoid Arthritis.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Certolizumab PegolBiological

    Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50.

  • PlaceboOther

    2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.

  • MethotrexateBiological

    The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects in Sustained Remission at Week 52Time frame: Week 52

Locations

178 sites in 22 countries. Site status is shown where the registry gives one.

  • 209

    Birmingham, Alabama

  • 170

    Huntsville, Alabama

  • 180

    Mobile, Alabama

  • 247

    Glendale, Arizona

  • 165

    Paradise Valley, Arizona

  • 234

    Paradise Valley, Arizona

  • 243

    Phoenix, Arizona

  • 251

    Tucson, Arizona

  • 160

    Covina, California

  • 257

    Hemet, California

  • 159

    Los Angeles, California

  • 201

    San Leandro, California

  • 202

    Upland, California

  • 172

    Whittier, California

  • 190

    Fort Lauderdale, Florida

  • 196

    Jupiter, Florida

  • 238

    Lake Mary, Florida

  • 232

    Miami, Florida

  • 213

    Naples, Florida

  • 214

    Ocala, Florida

  • 237

    Orange Park, Florida

  • 255

    Orlando, Florida

  • 163

    Palm Harbor, Florida

  • 166

    Plantation, Florida

  • 192

    Sarasota, Florida

  • 200

    Vero Beach, Florida

  • 226

    Coeur d'Alene, Idaho

  • 244

    Springfield, Illinois

  • 224

    South Bend, Indiana

  • 215

    Cedar Rapids, Iowa

  • 191

    Wichita, Kansas

  • 210

    Wichita, Kansas

  • 177

    Hagerstown, Maryland

  • 199

    Kalamazoo, Michigan

  • 198

    Eagan, Minnesota

  • 203

    Tupelo, Mississippi

  • 179

    St Louis, Missouri

  • 181

    Lincoln, Nebraska

  • 256

    Reno, Nevada

  • 229

    Lebanon, New Hampshire

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.